Trump and Mark Cuban Share a White House Stage to Roll Out 600 Generics on TrumpRx.gov, With Cost Plus Drugs Supplying 559 of Them and Amazon Pharmacy and GoodRx Layering Discounts
The expansion makes TrumpRx seven times larger than at its February launch, lists everyday medications like atorvastatin, lisinopril and metformin and is projected to cut out-of-pocket costs for Medicare beneficiaries by up to 12%.
President Donald Trump on Monday announced a dramatic expansion of TrumpRx.gov, the direct-to-consumer drug pricing portal launched in February, adding more than 600 generic medications to a platform that until this week listed only 43 branded products — and he did it standing on a White House stage alongside an unlikely partner: billionaire investor Mark Cuban.
The announcement, made in the South Court Auditorium of the Eisenhower Executive Office Building, was the result of partnership agreements with Amazon Pharmacy, GoodRx and Mark Cuban Cost Plus Drugs, which is supplying 559 of the 600 new generics being listed. Common medications immediately available through the portal include atorvastatin, the cholesterol drug sold for years under the Lipitor brand; clopidogrel, the antiplatelet drug used after stenting and heart attack; lisinopril, a workhorse for high blood pressure; and metformin, the first-line oral therapy for type 2 diabetes. Discounts negotiated by Amazon Pharmacy, Cost Plus Drugs and GoodRx will be displayed side-by-side on a single page so consumers can compare the cash price of each medication without involving an insurance company or pharmacy benefit manager.
Trump told reporters the platform has already saved Americans more than $400 million on prescription drugs in its first three months and is now seven times larger than it was on launch day in February. 'These are the drugs people actually take every morning,' Trump said, holding up a printed list of the new generics. The expansion does not include controlled substances, medications with FDA-mandated risk evaluation and mitigation strategies or specialty drugs that are not commonly available through direct-to-consumer channels.
The optics of the rollout drew nearly as much attention as the substance. Cuban, who spent much of the 2024 presidential cycle attacking Trump's economic agenda and stumping for Vice President Kamala Harris, told the crowd that 'Republicans want cheaper drugs, independents want cheaper drugs, Democrats want cheaper drugs, and together I think we're going to do something special.' When a reporter asked Trump how it felt to share a stage with one of his sharpest critics, the president quipped that Cuban 'made a mistake. It was a big mistake' — drawing laughs from administration officials including Health Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz and Food and Drug Administration Commissioner Marty Makary, who lined the back wall of the auditorium.
The TrumpRx expansion is part of a broader Trump second-term push to compress drug prices by routing around the traditional pharmacy benefit manager middleman, including 17 'most-favored-nation' pricing deals struck with major manufacturers that took effect in April. Patient advocacy groups gave the new generics rollout a cautious thumbs-up but warned that the portal still excludes biologics and a large swath of specialty oncology drugs where pricing pressure is most acute. Industry analysts at Leerink Partners said in a Tuesday note that the cumulative effect of TrumpRx and Cost Plus Drugs could shave 8 to 12 percent off out-of-pocket spending for the average Medicare Part D beneficiary on common chronic-disease prescriptions, but cautioned that the impact will depend on whether commercial insurers begin steering patients to the platform or treat it as a competitive threat.
Originally reported by The Hill.